Substance Dependence Clinical Trial
Official title:
A Placebo-controlled, Single Blind, Randomized Two Part Study Toinvestigate the Tolerability, Pharmacokinetics, and brainDopamine D3 Receptor Occupancy of Increasing Repeat Doses ofGSK618334 for up to 21 Days in Healthy Volunteers.
The proposed study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of repeated oral doses of GSK618334 in healthy male and female volunteers.
GSK618334 strongly binds to dopamine type 3 receptors in the human brain and is being developed as an innovative treatment for substance dependence. This study will evaluate the safety, tolerability, blood concentrations and effect following repeated oral doses of GSK618334 in healthy male and female volunteers. The effect of food on a single oral dose of GSK618334 will also be evaluated. Another portion of this study will investigate dopamine type 3 receptor binding in the human brain by PET scan before and after repeated doses of GSK618334. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00887367 -
EtOH Interaction Study
|
Phase 1 | |
| Completed |
NCT01189799 -
Motivational Therapy for Substance Users With Depression
|
N/A | |
| Completed |
NCT01381133 -
Adolescent Outpatient and Continuing Care Study
|
Phase 3 | |
| Recruiting |
NCT04430257 -
Pre-exposure Prophylaxis (PrEP) for Health
|
N/A | |
| Completed |
NCT01128140 -
Efficacy Trial of Warrior Check-Up
|
Phase 2 | |
| Completed |
NCT03767907 -
Online Cognitive Behavioural Therapy for Addiction: Efficacy and Cost-Effectiveness in a Pragmatic Clinical Trial
|
N/A | |
| Recruiting |
NCT05833399 -
Correlation of Genetic Variations With Clinical Response in Substance Use Disorder
|
||
| Withdrawn |
NCT01515917 -
Citicoline and Omega-3 Fatty Acid Effects in Veterans With Traumatic Brain Injury (TBI)
|
N/A | |
| Completed |
NCT00208143 -
Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia
|
Phase 4 | |
| Withdrawn |
NCT03762798 -
Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone
|
N/A | |
| Completed |
NCT03048552 -
Family Engagement, Cross-System Linkage to Substance Use Treatment for Juvenile Probationers -- Phase 3
|
N/A | |
| Active, not recruiting |
NCT04768920 -
Examining Feasibility and Acceptability of Telemedicine for Substance Use Disorder (SUD)
|
N/A | |
| Recruiting |
NCT05410561 -
Harnessing Telemedicine to Improve Alcohol Use Disorder Outcomes in Primary Care Patients
|
N/A | |
| Recruiting |
NCT05679284 -
A Cross-Sectional Observational Study on Retained Drug Needle Fragments in People Who Use Intravenous Drugs
|
||
| Withdrawn |
NCT00908206 -
Effects of GSK598809 on Brain Activation in Abstinent Alcoholics
|
Phase 1 | |
| Recruiting |
NCT05348317 -
Developing a Telehealth Model to Improve Treatment Access for Rural Veterans With Substance Use Disorders
|
N/A | |
| Recruiting |
NCT01741415 -
Distress Tolerance Treatment for Substance Users
|
Phase 2 | |
| Active, not recruiting |
NCT01621711 -
Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care
|
N/A | |
| Active, not recruiting |
NCT00609089 -
Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction
|
Phase 1/Phase 2 | |
| Completed |
NCT00288886 -
Reinforcement of Abstinence and Continuing Care in Substance Abuse Treatment
|
Phase 2 |